130 related articles for article (PubMed ID: 19765209)
1. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time: a rebuttal.
Kitchen S; Preston FE; Jennings I; Kitchen DP; Woods TA; Walker I
J Thromb Haemost; 2009 Dec; 7(12):2157-8; author reply 2178-9. PubMed ID: 19765209
[No Abstract] [Full Text] [Related]
2. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.
Cuker A; Ptashkin B; Konkle BA; Pipe SW; Whinna HC; Zheng XL; Cines DB; Pollak ES
J Thromb Haemost; 2009 Jan; 7(1):80-6. PubMed ID: 19017257
[TBL] [Abstract][Full Text] [Related]
3. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
Marlar RA; Clement B; Gausman J
Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time.
Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL
Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730
[TBL] [Abstract][Full Text] [Related]
5. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.
Samuel S; Allison TA; Sharaf S; Yau G; Ranjbar G; Mckaig N; Nguyen A; Escobar M; Choi HA
J Clin Pharm Ther; 2016 Oct; 41(5):499-502. PubMed ID: 27381025
[TBL] [Abstract][Full Text] [Related]
6. Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms.
Whitman-Purves E; Coons JC; Miller T; DiNella JV; Althouse A; Schmidhofer M; Smith RE
Clin Appl Thromb Hemost; 2018 Mar; 24(2):310-316. PubMed ID: 29212374
[TBL] [Abstract][Full Text] [Related]
7. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
Belk KW; Laposata M; Craver C
J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
[TBL] [Abstract][Full Text] [Related]
8. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
[TBL] [Abstract][Full Text] [Related]
9. Stability of the activated partial thromboplastin time used to monitor unfractionated heparin.
Ray M
J Thromb Haemost; 2008 Oct; 6(10):1817-9. PubMed ID: 18662258
[No Abstract] [Full Text] [Related]
10. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
[TBL] [Abstract][Full Text] [Related]
11. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
[TBL] [Abstract][Full Text] [Related]
12. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
[TBL] [Abstract][Full Text] [Related]
13. Performance Assessment of a Multifaceted Unfractionated Heparin Dosing Protocol in Adult Patients on Extracorporeal Membrane Oxygenator.
Al-Jazairi A; Raslan S; Al-Mehizia R; Dalaty HA; De Vol EB; Saad E; Alanazi M; Owaidah T
Ann Pharmacother; 2021 May; 55(5):592-604. PubMed ID: 32959678
[TBL] [Abstract][Full Text] [Related]
14. Limitations on point care APTT for monitoring of unfractionated heparin in intensive care patients.
Arachchillage DRJ; Vipond L; Laffan M
Thromb Res; 2019 Sep; 181():124-126. PubMed ID: 31400623
[No Abstract] [Full Text] [Related]
15. The effect of instrumentation and laboratory site on the accuracy of the APTT-based heparin therapeutic range.
Marlar RA; Gausman JN
Int J Lab Hematol; 2012 Dec; 34(6):614-20. PubMed ID: 22712447
[TBL] [Abstract][Full Text] [Related]
16. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
[No Abstract] [Full Text] [Related]
17. The PiCT
Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
[TBL] [Abstract][Full Text] [Related]
18. Protocolled Redefinition of the Therapeutic Range for Unfractionated Heparin: Lost in Translation?
Coene KLM; van der Graaf F; van de Kerkhof D
Clin Appl Thromb Hemost; 2018 Jan; 24(1):164-171. PubMed ID: 27856667
[TBL] [Abstract][Full Text] [Related]
19. An Overview of Heparin Monitoring with the Anti-Xa Assay.
Dean CL
Methods Mol Biol; 2023; 2663():343-353. PubMed ID: 37204722
[TBL] [Abstract][Full Text] [Related]
20. Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy.
Lawlor M; Gupta A; Ranard LS; Madhavan MV; Li J; Eisenberger A; Parikh SA; Sethi SS; Masoumi A
Thromb Res; 2021 Feb; 198():79-82. PubMed ID: 33302210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
